Trusted by:

clients clients clients clients clients clients clients clients clients clients

Not for public release

This news release is embargoed until 9-Dec-2024 3:05 AM EST Released to reporters: 4-Dec-2024 11:40 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2024 3:05 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

5-Dec-2024 2:55 PM EST
Children’s Hospital of Philadelphia Researchers Find Rotavirus Vaccine is Safe for Use in NICU Babies
Children's Hospital of Philadelphia

Researchers found that transmission of rotavirus vaccine strains in a neonatal intensive care unit (NICU) is rare and without clinical consequences, strongly suggesting that giving the rotavirus vaccine to eligible infants during their hospitalization provides immune benefits that outweigh any risks. The findings could serve as the basis for a change in clinical practice.

Newswise: Developing Wastewater Treatment Units That Treat Right Where It's Generated
Released: 9-Dec-2024 12:00 AM EST
Developing Wastewater Treatment Units That Treat Right Where It's Generated
National Research Council of Science and Technology

Dr. Sang Hoon Kim, Extreme Materials Research Center, Dr. Jong Min Kim, Materials Architecturing Research Center, and Dr. Sang Soo Han, Computation Science Research Center, all from the Korea Institute of Science and Technology (KIST), have developed an electrochemical device that can treat sewage and wastewater from pollution sites to the level of discharge. In particular, it can rapidly and completely decompose recalcitrant materials into inorganic substances and discharge them on its own.

Newswise: Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows
Released: 8-Dec-2024 4:30 PM EST
Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows
Roswell Park Comprehensive Cancer Center

Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.

Newswise: Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma
8-Dec-2024 12:30 PM EST
Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma
Roswell Park Comprehensive Cancer Center

The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.

6-Dec-2024 2:20 PM EST
ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma
Sylvester Comprehensive Cancer Center

ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

Released: 8-Dec-2024 11:10 AM EST
Multi-Center Study Shows Education Level, Income Impact Access to Stem Cell Transplantation for Acute Myeloid Leukemia Patients
Fred Hutchinson Cancer Center

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.

Newswise: Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
Released: 7-Dec-2024 7:00 PM EST
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
Roswell Park Comprehensive Cancer Center

A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates — FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

Newswise: Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
7-Dec-2024 12:30 PM EST
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
Roswell Park Comprehensive Cancer Center

Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

5-Dec-2024 9:00 AM EST
Keto Diet Metabolite May Power Up CAR T Cells to Kill Cancer
Perelman School of Medicine at the University of Pennsylvania

A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center, presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 4).


close
1.88874